Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4111 Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Introduction: Peptide receptor radionuclide therapy (PRRT) presents the possibility of tracing and quantifying the uptake of the drug in the body and performing dosimetry, potentially allowing individualization of treatment schemes. However, the details of how neuroendocrine tumors (NETs) respond to different absorbed doses are insufficiently known.

Conference:

Presenting Author: Warfvinge C

Authors: Warfvinge C, Gustafsson J, Roth D, Tennvall J, Svensson J,

Keywords: PRRT, Neuroendocrine tumor, dose-response, dosimetry,

#3800 Correlation between early response and lesion dosimetry in patients with advanced neuroendocrine tumor (NET) treated with radioligand therapy (RLT)

Introduction: The identification of predictive parameters of response to radioligand therapy (RLT) in NET patients is essential in order to avoid futile therapy toxicities. The relation between the tumor absorbed dose and therapy response has so far not been established.

Conference:

Presenting Author: Durmo R

Authors: Durmo R, Fioroni F, Grassi E, Coruzzi C, Giulia B,

Keywords: RLT, Dosimetry,

#3563 Can tumor absorbed dose predict response to Peptide Receptor Radionuclide Therapy (PRRT) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)?

Introduction: Tumor dosimetry protocols following Peptide Receptor Radionuclide Therapy (PRRT) have not yet been standardised and tumor absorbed dose does not hold clear value in predicting response to treatment.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, Marin G, Levillain H, van Bogaert C, Critchi G,

Keywords: PRRT, tumor dose, 68Ga-DOTATATE, SUVmax, response,

#3270 Exploration of Ga-68 DOTA PET radiomics to predict the absorbed dose of Lu-177 DOTATATE® therapy of midgut neuroendocrine tumors

Introduction: Lu-177 DOTATATE® is a proficient systemic irradiation with heterogeneous individual consequences due to tumor burden, uptake and elimination. Current dosimetry protocols seem not accurate enough to predict efficacy or toxicity.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Courbon F

Authors: Brahmi S, Vallot D, Vija L, Dierickx L, Courbon F,

Keywords: midgut NET, Ga DOTA PET CT, LuPRRT, PET metrics, SUV, tumor absorbed dose,

#588 CORRELATION OF TUMOR ABSORBED DOSES OF 177LU-DOTA-TATE TREATMENT WITH PRE-THERAPEUTIC GA68 DOTA-TATE PET/CT UPTAKE IN NEUROENDOCRINE TUMORS

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 aroused great interest. Estimation of actual radiation doses to tumors may help therapy planning.

Conference:

Presenting Author:

Authors: demirci e, kabasakal l, toklu t, ocak m, yeyin n,

Keywords: Tumor absorbed doses, PRRT, PET,